Virtual ACC 2020 | CARAVAGGIO: Apixaban in Venous Thromboembolism Associated to Cancer

Oral apixaban resulted non-inferior to subcutaneous dalteparin in the treatment of venous thromboembolism associated to cancer with no increase in major bleeding.

The most recent guidelines recommend the use of edoxaban or rivaroxaban for the treatment of venous thromboembolism associated to cancer.  However, the evidence of new anticoagulants in this context is limited and the greatest concern is bleeding increase. 

The CARAVAGGIO randomized over 1100 consecutive patients consecutive patients with cancer who had symptomatic or incidental acute proximal deep-vein thrombosis or pulmonary embolism to receiving apixaban (10 mg twice a day for a week and 5 mg a day thereafter) vs subcutaneous dalteparin (200 UI/kg once a day for the first month followed by 150 UI/kg a day). The treatment was administered for 6 months. 

Recurrent thromboembolism (primary efficacy end point) occurred in 5.6% of patients in the apixaban group vs 7.9% in the dalteparin group (p<0.001 for non-inferiority).


Read also: Virtual ACC 2020 | PRECOMBAT: 10 Years for Surgery vs. Angioplasty in Left Main Coronary Artery Disease.


Major bleeding happened in 3.8% of patients in the apixaban group vs 4% in the dalteparin group (p=0.6).

Conclusion

Oral apixaban resulted non-inferior to subcutaneous dalteparin in the treatment of venous thromboembolism associated to cancer with no increase in major bleeding risk. 

caravaggio

Original Title: Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.

Reference: Giancarlo Agnelli et al. NEJM online before print y presentado en forma virtual en el ACC 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...